Haemophilia Journal publishes the NHF-McMaster University Guideline on Care Models for Hemophilia Management.
A statement from NHF CEO Val D. Bias on a recent article published in PLOS Medicine.
Encouraging results from a phase I/II clinical trial of SPK-9001, the company’s novel investigational hemophilia B gene therapy.
Preliminary data from a low-dose group were presented at the 21st Congress of the European Hematology Association in Copenhagen, Denmark.
New drug is the first recombinant single-chain therapy. Its long-lasting action may allow some patients to infuse twice weekly.
NHF is honored to receive the highest designation, which is only given to 5% of nonprofit organizations.
MASAC Document #242 is a valuable resource for understanding supply of clotting factor concentrate doses for home use by individuals with bleeding disorders.
Combined company is expected to be the global leader in the treatment of many rare diseases.
Chugai's novel prophylactic therapy for people with hemophilia A is administered through a subcutaneous injection.
Researchers found that previously-untreated patients (PUPs) had a significantly higher incidence of inhibitors when treated with recombinant factor VIII than those treated with plasma-derived factor VIII.
eNewsletter Sign Up
Steps for Living
Victory for Women
Donate Your Car